Area of research
Surgery · Molecular Biology
Research interest
Research interests include Protein Degradation and Inhibitors, Barrier Structure and Function Studies, Bladder and Urothelial Cancer Treatments, and Cancer Immunotherapy and Biomarkers.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application